ScaleReady, a joint venture between Bio-Techne Fresenius Kabi, and Wilson Wolf, launched on January 6, 2021. The new company brings together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing from its founding partners. ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry, enhancing the prospects of success for cell and gene therapy organizations. The new company will accelerate innovation in cell and gene therapy manufacturing, building on the R&D pipelines of its founding partners and through global technology partnerships with industry and academic leaders. Through this partnership, ScaleReady provides sales, marketing, and application support for tools and technologies used in cell and gene therapy manufacturing worldwide. Wilson Wolf’s G-Rex® cell culture technology, Fresenius Kabi’s Lovo and upcoming Cue cell processing systems, and Bio-Techne’s range of GMP proteins, reagents, media, and gene editing technologies, are all part of the ScaleReady manufacturing platform. With cell and gene therapies showing great potential for a wide range of diseases, the need for reliable and consistent raw material supply has never been more important.